🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT06884189
Recruiting Observational

Application of Plant Protection Products (PPP) in Apple Orchards

NCT06884189 · tracked via the Priya Life Science Germany tracker
Sponsor
German Federal Institute for Risk Assessment
Phase
Observational
Started
2025-03-11
Last updated
2025-03-19

Condition(s) studied

Dermal ExposureInhalative ExposureMetabolites in UrineEffekt Biomarker in Blood

Study summary

The aim of the aPPPle pilot study is to test feasibility and generate first results in preparation for a main study. The aPPPle study will investigate the exposure of operators, workers and residents to plant protection products (PPP) and potential physiological effects on blood biomarkers. The target plants are apple crops, as application occurs at higher altitudes and therefore higher drift/exposure is expected compared to ground-level application. The substances to be investigated are acetamiprid (an insecticide) and dithianon and dodine (two fungicides).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * belonging to one of the defined study groups * over 18 years of age at the time of recruitment * person can understand the language and content of the study requirements * person is capable of consenting to participate in the study and has given written consent to participate in the aPPPle study * person has health insurance Exclusion Criteria for residents and control: person has direct professional contact with the tested substances acetamiprid, dithianon or dodine

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Federal Institute for Risk Assessment Berlin Germany Recruiting

More German Federal Institute for Risk Assessment trials in Germany

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06884189 on ClinicalTrials.gov ↗ ← All trials in Germany